Edwin Liu
Concepts (356)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 65 | 2026 | 308 | 10.580 |
Why?
| | Autoantibodies | 49 | 2026 | 1497 | 3.090 |
Why?
| | Transglutaminases | 28 | 2025 | 159 | 2.970 |
Why?
| | Diet, Gluten-Free | 13 | 2026 | 56 | 2.050 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 173 | 1.870 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 464 | 1.520 |
Why?
| | Autoimmunity | 23 | 2024 | 925 | 1.470 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 153 | 1.370 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3838 | 1.330 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2407 | 1.230 |
Why?
| | Peptide Fragments | 15 | 2008 | 706 | 1.220 |
Why?
| | Insulin | 24 | 2009 | 2502 | 1.180 |
Why?
| | Glutens | 10 | 2023 | 59 | 0.940 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 76 | 0.870 |
Why?
| | Islets of Langerhans | 17 | 2017 | 833 | 0.830 |
Why?
| | Rett Syndrome | 1 | 2024 | 40 | 0.820 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 219 | 0.730 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 209 | 0.720 |
Why?
| | Insulin Antibodies | 11 | 2013 | 103 | 0.720 |
Why?
| | Patient Compliance | 3 | 2026 | 612 | 0.710 |
Why?
| | Nutrition Therapy | 1 | 2020 | 36 | 0.630 |
Why?
| | Child | 46 | 2026 | 22440 | 0.620 |
Why?
| | Genetic Testing | 6 | 2015 | 475 | 0.610 |
Why?
| | Pyrrolidinones | 1 | 2019 | 30 | 0.600 |
Why?
| | Child, Preschool | 33 | 2026 | 11630 | 0.600 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 615 | 0.550 |
Why?
| | Nutritionists | 3 | 2026 | 24 | 0.530 |
Why?
| | Down Syndrome | 2 | 2023 | 523 | 0.520 |
Why?
| | Immunoglobulin A | 9 | 2025 | 218 | 0.510 |
Why?
| | Anticonvulsants | 1 | 2019 | 228 | 0.510 |
Why?
| | Mass Screening | 8 | 2024 | 1325 | 0.500 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 202 | 0.470 |
Why?
| | Intestinal Mucosa | 5 | 2026 | 665 | 0.460 |
Why?
| | Humans | 88 | 2026 | 143821 | 0.450 |
Why?
| | Infant | 27 | 2025 | 9885 | 0.440 |
Why?
| | Epilepsy | 1 | 2019 | 375 | 0.430 |
Why?
| | Anaphylaxis | 3 | 2004 | 102 | 0.410 |
Why?
| | Poly I-C | 4 | 2008 | 56 | 0.400 |
Why?
| | Adolescent | 26 | 2026 | 22233 | 0.390 |
Why?
| | Depression | 2 | 2022 | 1520 | 0.390 |
Why?
| | Caregivers | 1 | 2022 | 1025 | 0.380 |
Why?
| | Female | 59 | 2026 | 77570 | 0.380 |
Why?
| | Gliadin | 3 | 2018 | 13 | 0.370 |
Why?
| | Radioimmunoassay | 3 | 2016 | 167 | 0.350 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2167 | 0.350 |
Why?
| | Male | 50 | 2026 | 71569 | 0.340 |
Why?
| | Prospective Studies | 21 | 2024 | 7900 | 0.340 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5316 | 0.340 |
Why?
| | Jejunum | 1 | 2011 | 35 | 0.330 |
Why?
| | Telemedicine | 1 | 2020 | 940 | 0.330 |
Why?
| | Biopsy | 11 | 2025 | 1068 | 0.330 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 246 | 0.320 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 99 | 0.310 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1984 | 0.300 |
Why?
| | Quality of Life | 5 | 2024 | 3142 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 54 | 0.290 |
Why?
| | Risk Factors | 17 | 2024 | 10623 | 0.290 |
Why?
| | Luminescent Measurements | 2 | 2020 | 76 | 0.290 |
Why?
| | Dietary Proteins | 2 | 2019 | 136 | 0.280 |
Why?
| | Laboratories | 1 | 2009 | 111 | 0.270 |
Why?
| | Interferon-alpha | 2 | 2005 | 184 | 0.260 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.260 |
Why?
| | Poly A-U | 1 | 2006 | 3 | 0.250 |
Why?
| | Mice | 32 | 2013 | 18421 | 0.250 |
Why?
| | Immune Tolerance | 4 | 2013 | 378 | 0.240 |
Why?
| | Europe | 6 | 2017 | 410 | 0.240 |
Why?
| | T-Lymphocytes | 7 | 2008 | 2041 | 0.240 |
Why?
| | Serologic Tests | 4 | 2021 | 53 | 0.230 |
Why?
| | Time Factors | 10 | 2025 | 7068 | 0.220 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2026 | 62 | 0.220 |
Why?
| | HLA Antigens | 5 | 2019 | 227 | 0.220 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.220 |
Why?
| | Dyspepsia | 1 | 2024 | 10 | 0.220 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2097 | 0.210 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 856 | 0.210 |
Why?
| | CD4 Antigens | 2 | 2003 | 144 | 0.210 |
Why?
| | Antibodies | 3 | 2014 | 399 | 0.210 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 54 | 0.200 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 65 | 0.200 |
Why?
| | Genotype | 7 | 2019 | 1837 | 0.200 |
Why?
| | Autoantigens | 6 | 2009 | 429 | 0.200 |
Why?
| | Animals | 34 | 2015 | 38140 | 0.200 |
Why?
| | Peptides | 3 | 2018 | 986 | 0.200 |
Why?
| | Iron | 1 | 2026 | 355 | 0.200 |
Why?
| | Diet | 4 | 2019 | 1266 | 0.200 |
Why?
| | Abdominal Pain | 1 | 2024 | 145 | 0.190 |
Why?
| | Endosonography | 1 | 2024 | 157 | 0.190 |
Why?
| | Biomarkers | 7 | 2025 | 4248 | 0.190 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1270 | 0.180 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 726 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 547 | 0.180 |
Why?
| | Ileal Diseases | 1 | 2001 | 13 | 0.180 |
Why?
| | Prevalence | 4 | 2026 | 2819 | 0.180 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 27 | 0.180 |
Why?
| | Catheterization | 2 | 2001 | 182 | 0.170 |
Why?
| | Colonic Diseases | 1 | 2001 | 36 | 0.170 |
Why?
| | Comorbidity | 2 | 2024 | 1638 | 0.170 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1305 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2182 | 0.160 |
Why?
| | Dietetics | 1 | 2020 | 24 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 525 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 92 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2024 | 584 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1133 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2019 | 6362 | 0.150 |
Why?
| | Incidence | 5 | 2022 | 2845 | 0.150 |
Why?
| | Vaccines | 1 | 2004 | 387 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 83 | 0.150 |
Why?
| | Immunization | 4 | 2007 | 375 | 0.150 |
Why?
| | Probiotics | 1 | 2019 | 61 | 0.140 |
Why?
| | Duodenum | 3 | 2023 | 78 | 0.140 |
Why?
| | Cross-Sectional Studies | 4 | 2026 | 5761 | 0.140 |
Why?
| | Risk | 3 | 2019 | 901 | 0.140 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1088 | 0.140 |
Why?
| | Risk Assessment | 8 | 2020 | 3556 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 219 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 360 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2026 | 16754 | 0.130 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1522 | 0.130 |
Why?
| | Anxiety | 2 | 2022 | 1100 | 0.130 |
Why?
| | Parents | 2 | 2024 | 1414 | 0.120 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 15 | 0.120 |
Why?
| | United States | 9 | 2025 | 15602 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 48 | 0.120 |
Why?
| | Feces | 1 | 2019 | 506 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 78 | 0.120 |
Why?
| | Cesarean Section | 1 | 2018 | 224 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 62 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 185 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6004 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2020 | 791 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4553 | 0.110 |
Why?
| | Reproducibility of Results | 4 | 2026 | 3392 | 0.110 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 90 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 75 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2021 | 899 | 0.100 |
Why?
| | Case-Control Studies | 6 | 2019 | 3614 | 0.100 |
Why?
| | Homozygote | 1 | 2014 | 201 | 0.100 |
Why?
| | Weight Gain | 1 | 2017 | 559 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 439 | 0.100 |
Why?
| | ROC Curve | 3 | 2013 | 607 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 197 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 3120 | 0.100 |
Why?
| | Clonal Anergy | 1 | 2013 | 55 | 0.090 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 13 | 0.090 |
Why?
| | Child Development | 1 | 2017 | 494 | 0.090 |
Why?
| | Mice, SCID | 4 | 2008 | 377 | 0.090 |
Why?
| | Cohort Studies | 6 | 2025 | 5861 | 0.090 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 163 | 0.090 |
Why?
| | Young Adult | 5 | 2024 | 13914 | 0.090 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 80 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2148 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | Protein Precursors | 2 | 2003 | 135 | 0.090 |
Why?
| | Sweden | 3 | 2017 | 112 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1078 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 957 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 501 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 444 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1675 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4578 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2024 | 11459 | 0.080 |
Why?
| | Heterozygote | 2 | 2016 | 315 | 0.080 |
Why?
| | Adenoviridae | 2 | 2019 | 203 | 0.080 |
Why?
| | Proinsulin | 3 | 2008 | 52 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1901 | 0.080 |
Why?
| | Plant Proteins | 1 | 2011 | 112 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 318 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 682 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 30 | 0.080 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 6032 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 945 | 0.070 |
Why?
| | Radioligand Assay | 1 | 2009 | 37 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1402 | 0.070 |
Why?
| | Bilirubin | 2 | 2008 | 87 | 0.070 |
Why?
| | Ammonia | 2 | 2008 | 62 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 25 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 31 | 0.070 |
Why?
| | Prediabetic State | 3 | 2009 | 257 | 0.070 |
Why?
| | Decision Support Techniques | 1 | 2013 | 446 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2926 | 0.070 |
Why?
| | Dietary Supplements | 2 | 2026 | 576 | 0.070 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 12 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 164 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 517 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 184 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2871 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 370 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 30 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 55 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 103 | 0.060 |
Why?
| | Disease Susceptibility | 2 | 2020 | 351 | 0.060 |
Why?
| | Self-Help Groups | 1 | 2007 | 37 | 0.060 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 205 | 0.060 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Adult | 8 | 2023 | 40129 | 0.060 |
Why?
| | Blood Glucose | 3 | 2006 | 2325 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 791 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 126 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 306 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 294 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2095 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 41 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2030 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 166 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1080 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 3288 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 23 | 0.050 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 9 | 0.050 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 109 | 0.050 |
Why?
| | Survival Rate | 2 | 2007 | 2034 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2914 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 60 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 99 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 889 | 0.050 |
Why?
| | Canada | 1 | 2025 | 425 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 175 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 179 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 338 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 267 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 100 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 563 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 490 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 20 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 160 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 6 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 30 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1502 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2620 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 39 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 894 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 44 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 366 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 69 | 0.040 |
Why?
| | Oligopeptides | 1 | 2003 | 267 | 0.040 |
Why?
| | Immunotherapy | 1 | 2007 | 669 | 0.040 |
Why?
| | Paracentesis | 1 | 2001 | 15 | 0.040 |
Why?
| | Gastroschisis | 1 | 2001 | 32 | 0.040 |
Why?
| | Ascites | 1 | 2001 | 47 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 31 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 156 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 728 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4210 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1512 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 98 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 465 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1358 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 865 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1843 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 287 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 85 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 269 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 255 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1525 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1851 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5609 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2948 | 0.030 |
Why?
| | Metagenomics | 1 | 2019 | 179 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 121 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 491 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 286 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 163 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 37 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 639 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 482 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 806 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1688 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3183 | 0.030 |
Why?
| | China | 1 | 2016 | 225 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 779 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 260 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1735 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 179 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 516 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 193 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 127 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 102 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1414 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 681 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 82 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1968 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 483 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1733 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 312 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 354 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2186 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 711 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1327 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 135 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 250 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 395 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 841 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 165 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2439 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2078 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 573 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 533 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 769 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 421 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 63 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 395 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 379 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 13 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7154 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 35 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 21 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 15 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 37 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 77 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2242 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2894 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1143 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 23 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 269 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 243 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 376 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 16 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 39 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 93 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 188 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 335 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 294 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2013 | 4172 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 22 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 638 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 40 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 169 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 105 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2906 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 543 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 70 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 74 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2590 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 39 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1826 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 564 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 229 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 106 | 0.010 |
Why?
| | Needles | 1 | 2001 | 61 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 184 | 0.010 |
Why?
| | Safety | 1 | 2001 | 352 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 883 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 853 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3073 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 35630 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 4106 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|